Aldeyra Therapeutics (ALDX) Stock Price
$2.18 0%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
2 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Aldeyra Therapeutics, AI stock picks, stock alerts and much more.
ALDX AI Stock Analysis
AI stock analysis for ALDX is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Aldeyra Therapeutics (ALDX) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Aldeyra Therapeutics (ALDX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Aldeyra Therapeutics (ALDX), currently trading at $2.18, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About ALDX
-
Aldeyra Therapeutics, Inc.
-
Symbol
ALDX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
130.6M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$23.37 2.7% |
6 |
 |
Inovio Pharmaceuticals INO |
$1.8 1.1% |
1 |
 |
Moderna MRNA |
$24.25 0.5% |
3 |
 |
Anavex Life Sciences AVXL |
$8.25 3.6% |
5 |
 |
BridgeBio Pharma BBIO |
$34.17 2% |
6 |
News
ALDX Alternative Data
Web Traffic
Aldeyra Therapeutics receives an estimated 15476 monthly visitors to aldeyra.com, which is up by 118.9% over the last month.
-
Web Traffic
15476
-
Change from Previous Month
118.9%
-
3 Month Change
104.7%
-
YoY Change
104.7%
Twitter Followers
Aldeyra Therapeutics has 466 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.1% over the last month.
-
Twitter Followers
466
-
Daily Change
0%
-
1 Month Change
1.1%
-
3 Month Change
6.4%
-
YoY Change
6.4%
Facebook Engagement
Aldeyra Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Followers
3,914 are following Aldeyra Therapeutics on LinkedIn, up by 1.2% over the last month.
-
LinkedIn Followers
3914
-
Daily Change
0%
-
1 Month Change
1.2%
-
3 Month Change
3.9%
Job Postings
Aldeyra Therapeutics currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Aldeyra Therapeutics has 14 employees.
-
LinkedIn Employees
14
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
6.7%
-
YoY Change
6.7%
Reddit Mentions
Aldeyra Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
News Mentions
Aldeyra Therapeutics was mentioned 2 times in the news yesterday.
-
News Mentions
2
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Aldeyra Therapeutics is 100 out of 100 (very bullish).
-
Business Outlook
100
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
ALDX Financials
ALDX Key Metrics
-
Total Revenue
$244.5K
-
Net Income
-$15.8M
-
Earnings per Share
$0.67
-
Free cash flow
-$12M
-
EBITDA
-$15.3M
-
EBITDA Ratio
-62.4618
-
Total Assets
$104.6M
ALDX 2-year Revenue & Income
ALDX 2-year Free Cash Flow
ALDX Technicals
ALDX SMA
ALDX RSI
FAQ
What's the current price of Aldeyra Therapeutics (ALDX) Stock?
The price of an Aldeyra Therapeutics (ALDX) share is $2.18.
What's the market cap of Aldeyra Therapeutics?
The current market cap of Aldeyra Therapeutics is 130.6M.
Should I buy or sell ALDX?
Aldeyra Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Aldeyra Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Aldeyra Therapeutics a good investment?
The current analysis of Aldeyra Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Aldeyra Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Aldeyra Therapeutics (ALDX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Aldeyra Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Aldeyra Therapeutics (ALDX) that investors often compare it to?
Aldeyra Therapeutics (ALDX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Aldeyra Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Aldeyra Therapeutics' stock price to be around $2.16 in 2026. Starting from the current price of $2.18, this represents a 1.1% change in price, indicating a neutral outlook for the stock.
How to buy Aldeyra Therapeutics (ALDX) Stock?
Aldeyra Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Aldeyra Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.